But in fact, if it weren’t for middlemen like wholesalers and pharmacy benefit managers, drug prices would be even higher. When Donald Trump was running for President in 2016, he promised to ...

The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs ...

Drug middlemen paid their own mail-order pharmacies as much as 200 times more than rival pharmacies for common cancer medicines, generating at least $1 billion in excess revenue and potentially ...

If Democrats focused more on why drugs’ list prices have increased so much instead of capping out-of-pocket costs in Medicare, “we could have not only solved the problem for insulin but for ...

The middlemen companies negotiate rebates and discounts for insurance plans from drug manufacturers, determining the prices insurance plans pay and pharmacies receive. “People hate PBMs.

Americans pay more for prescription drugs than any country in the world, and the pharmaceutical industry earns billions in profits each year. Critics blame pharmacy benefit managers, or PBMs, for ...

US Drug Industry Middlemen Defend Business Model Amid Accusations of Raising Patient Costs By Amina Niasse and Bhanvi Satija (Reuters) -U.S. pharmaceutical industry middlemen defended their role ...

"When you're filling the prescription, the PBM tells you the patient pays $20 for this drug, we'll pay you $100," Hoey said. "As the pharmacist, I say, OK, I get a total of $120 for a drug that ...

FTC probing drug ‘middlemen’ over ‘critical’ generic shortages at hospitals: ‘Endangering patients’ By . Reuters. Published Feb. 14, 2024, 11:29 a.m. ET. Explore More ...

Drug middlemen, known as pharmacy-benefit managers, have accomplished something rare in Washington: Their business practices have led to a bipartisan consensus of sorts around the need for more ...

The Federal Trade Commission’s new report on prescription drug middlemen paints a stark picture. Not only for patients caught in the crosshairs of organizations’ pharmacy benefit managers but ...